A Comparator Trial on the Relative Efficacy of Two Triglyceride Forms of Fish Oil

• Male or female adults aged 18 - 35 (inclusive)
• Healthy as determined from medical history
• Non-smoker, or ex-smoker ≥6 months
• Body mass index 18.5 - 24.9 kg/m2
• Female participants of childbearing potential (i.e. not surgically sterilized or post-menopausal greater than one year) must have negative urine pregnancy test and must be using an effective birth control method
• Willing to avoid alcohol consumption for 24 h prior to every clinic visit
• Willing to maintain a stable body weight, activity level and dietary pattern except for use of the study products, as directed
• Willing and able to provide informed written consent

Exclusion Criteria:

• Individuals taking prescription or non-prescription health products that may affect the study endpoint (e.g. corticosteroids, prescription anti-inflammatory drugs, blood lipid-lowering drugs (e.g. statins, fibrates, bile acid exchanger resin, phytosterols, niacin or its analogues, carnitine, etc.) in the previous 6 months
• Individuals taking any supplements with omega-3 fatty acids, phytosterols, polyglucosamines (Chitosan) or other lipid-binding ingredients in the previous 6 months
• Individuals who consume omega-3 fatty acid rich fish (salmon, mackerel, herring) more than twice per month
• Unstable use (initiation or change in dose) of antihypertensive medications or thyroid hormone replacement medications within 3 months prior to visit 1
• Use of any weight-loss programs or weight-loss medications (prescription or over-the counter) including, but not limited to, lipase inhibitors, within 6 months prior to visit 1 and throughout the study
• Pregnancy or lactation, or participant unwilling to take appropriate contraceptives for the duration of the study
• History of blood clotting disorders or use of coagulation-inhibiting drugs (e.g. warfarin)
• Presence of major diseases such as diabetes, gastrointestinal, endocrine, cardiovascular, renal, or liver disease
• History of neurological disease (e.g. Parkinson's disease, stroke, traumatic brain injury, etc.)
• History of cancer (excluding non-melanoma skin cancer and basal cell carcinoma) in past 5 years
• Uncontrolled hypertension defined as a seated resting systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg
• Abnormal laboratory test results of clinical significance, including, but not limited to, ALT or AST ≥1.5X the upper limit of normal at screening (visit 1)
• Triglycerides ≥400 mg/dL (≥4.52mmol/L) at screening (visit 1)
• Presence or history (past 6 months) of alcohol or drug abuse; alcohol use of >2 standard alcoholic drinks per day
• Participant has a known allergy or intolerance to fish/fish oil or any of the ingredients in the test products
• Participant is vegan
• Participant is unwilling or unable to abide by the requirements of the protocol
• Any condition that would interfere with the participant's ability to comply with study instructions, might confound the interpretation of the study, or put the participant at risk
• Participant has taken an investigational medicine or has participated in a research study within 30 days prior to the first study visit